Scroll Back to Top


Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Idoko Salifu (a), Navneet Singh (b), Maria Berraondo (a), Jordi Remon (c), Stephanie Salifu (d),
Eric Severson (a), Angela Quintana (e), Sandra Peir´o (e), Shakti Ramkissoon (a,f), Laura Vidal (a),
Isagani Chico (a), Kamal S. Saini (a,g)

a Labcorp Drug Development Inc., Princeton, NJ, USA
b Postgraduate Institute of Medical Education and Research, Chandigarh, India
c Paris-Saclay University, department of Cancer Medicine, Gustave Roussy, Villejuif, France
d Dix Hills, NY, USA
e Vall d’Hebron Institute of Oncology, Barcelona, Spain
f Department of Pathology, Wake Forest School of Medicine and Comprehensive Cancer Center, Winston-Salem, NC, USA
g Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK